Core Viewpoint - The document outlines the management system for the shares held by directors and senior management of He Yuan Biotechnology (Shanghai) Co., Ltd, emphasizing compliance with relevant laws and regulations regarding share trading and disclosure [1][2]. Summary by Sections General Principles - The system aims to strengthen the management of shares held by directors and senior management, clarifying procedures based on various laws and regulations [1]. - It applies to directors, senior management, and core technical personnel regarding their shareholdings and changes [1]. Shareholding Change Rules - Directors and senior management must be aware of laws prohibiting insider trading and market manipulation before trading shares [2]. - Shares held by directors and senior management include those registered in their names and those held through others' accounts [2]. - They are prohibited from engaging in margin trading with the company's shares [2]. Restrictions on Share Transfer - Shares cannot be transferred under specific conditions, such as within one year of the company's stock listing or within six months after leaving the company [4]. - Additional restrictions apply if the company is under investigation for securities violations or if the individual is subject to administrative penalties [4]. Trading Restrictions - Directors and senior management are prohibited from trading shares during certain periods, such as 15 days before annual or semi-annual reports [6]. - A six-month prohibition on reverse trading applies after any legal purchase or sale of shares [7]. Reporting and Disclosure Management - The company secretary is responsible for managing the identity and shareholding data of directors and senior management, ensuring compliance with reporting requirements [7]. - Any changes in shareholdings must be reported within two trading days, including details of the transaction [18]. Legal Responsibilities - The company reserves the right to pursue accountability for violations of the management system by directors and senior management [24]. - Individuals causing losses to investors due to violations may face civil, administrative, or criminal liabilities [25]. Additional Provisions - The system will be revised in accordance with future laws and regulations, ensuring compliance with the company's articles of association [12].
和元生物: 《董事和高级管理人员所持公司股份及其变动管理制度》(2025年6月制定)